Semaglutide for Insulin Resistance: Evidence, Eligibility

Semaglutide is not FDA approved for insulin resistance. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Brands: Ozempic, Wegovy and Rybelsus
Best result (STEP 1): 14.9% weight loss

Wegovy overview

How long it remains in your body

About 1 week is the half-life. By 7 d, half has cleared. Following five half-lives (35 d), about 3% is left.

Weight loss in its main trial

In STEP 1 over 68 weeks, 14.9% of body weight was lost, compared with 2.4% on placebo.

Cost over time

Monthly prices in US dollars include the list price and self-pay offers, each taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Semaglutide: who qualifies
Who sets the rule	Who qualifies
Ozempic	Used with diet and exercise, it lowers blood sugar in adults with type 2 diabetes.
Ozempic	In adults with type 2 diabetes and heart disease, it reduces the risk of heart attack, stroke, and heart-related death.
Ozempic	In adults with type 2 diabetes and chronic kidney disease, it reduces the risk of worsening kidney disease, kidney failure, and heart-related death.
Wegovy	In adults with heart disease who have obesity or overweight, it reduces the risk of heart attack, stroke, and heart-related death (injection and tablets).
Wegovy	With diet and activity, it supports weight loss and maintaining the loss over the long term. This applies to adults and children age 12 and older with obesity, plus adults who have overweight and a weight-related condition.
Wegovy	The injection treats MASH liver disease with moderate to advanced scarring in adults (no cirrhosis).
Wegovy	In adults, the tablets have approval to help with weight loss and reduce the risk to your heart.
Rybelsus	Used with diet and exercise, it lowers blood sugar in adults with type 2 diabetes.
Rybelsus	For adults with type 2 diabetes at high risk, it reduces the risk of heart attack, stroke, and heart-related death.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Heart failure, uncontrolled blood pressure, or CKD 3a+ is required, along with BMI 30 or higher
Medicare GLP-1 Bridge	BMI of 27 or higher, plus prediabetes, PAD, or an earlier heart attack or stroke
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a program of diet and activity lasting 6 months must come first

Sources: medicare.gov 1 2, aetna.com, FDA label (DailyMed) 1 2 3.

Trial results for insulin resistance

Not one trial focused only on people with insulin resistance. Every adult studied had obesity or overweight and did not have diabetes.

Semaglutide trials for insulin resistance
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Source for the study: STEP 1 (FDA label (DailyMed)).

What changes with insulin resistance?

Label details on semaglutide and insulin resistance
What changes	What the label says	Labels
Hypoglycemia during concomitant use of either insulin secretagogues or insulin	Combining it with insulin or a sulfonylurea raises the risk of low blood sugar, so those doses may need to be lowered.	All of them
Taken with insulin or sulfonylureas	If you combine it with insulin or a sulfonylurea, such as glipizide or glimepiride, low blood sugar is more likely. Your doctor may lower those doses.	All of them

According to the FDA labels: FDA label on DailyMed.

These label warnings come from: FDA label (DailyMed).

Coverage options for insulin resistance

Medicare Part D does not cover a GLP-1 used only for weight loss.

Wegovy is listed at $50 per month under the Medicare GLP-1 Bridge rules if you qualify.

When Medicaid covers weight-loss GLP-1s, prior authorization is standard practice

Sources: humana.com, CMS, KFF.

Alternatives for insulin resistance

GLP-1 medicines and insulin resistance
Medicine	For insulin resistance	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed